Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in the BofA Securities 2025 Healthcare Conference. The company will engage in a fireside chat on May 14, 2025, at 3:40 p.m. PT in Las Vegas, NV. Investors can access a live webcast of the presentation through the "News and Events" section of Kymera's website, with a replay available after the event.
Kymera Therapeutics (NASDAQ: KYMR), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci orali a piccole molecole degradanti per malattie immunologiche, ha annunciato la sua partecipazione alla BofA Securities 2025 Healthcare Conference. L'azienda parteciperà a una conversazione informale il 14 maggio 2025, alle 15:40 PT a Las Vegas, NV. Gli investitori potranno seguire la presentazione in diretta streaming tramite la sezione "News and Events" del sito web di Kymera, con la possibilità di rivederla in replay dopo l'evento.
Kymera Therapeutics (NASDAQ: KYMR), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos orales de moléculas pequeñas degradadoras para enfermedades inmunológicas, ha anunciado su participación en la BofA Securities 2025 Healthcare Conference. La compañía participará en una charla informal el 14 de mayo de 2025 a las 3:40 p.m. PT en Las Vegas, NV. Los inversores podrán acceder a una transmisión en vivo de la presentación a través de la sección "News and Events" del sitio web de Kymera, con una repetición disponible después del evento.
Kymera Therapeutics (NASDAQ: KYMR)는 면역 질환 치료를 위한 경구용 소분자 분해제 의약품 개발에 주력하는 임상 단계 바이오제약 회사로, BofA Securities 2025 Healthcare Conference에 참가한다고 발표했습니다. 회사는 2025년 5월 14일 오후 3시 40분(태평양 시간) 라스베이거스, NV에서 진행되는 대화식 세션에 참여할 예정입니다. 투자자들은 Kymera 웹사이트의 "News and Events" 섹션을 통해 발표를 실시간 웹캐스트로 시청할 수 있으며, 행사 후 다시보기 서비스도 제공됩니다.
Kymera Therapeutics (NASDAQ : KYMR), une société biopharmaceutique en phase clinique spécialisée dans le développement de médicaments oraux à petites molécules dégradantes pour les maladies immunologiques, a annoncé sa participation à la BofA Securities 2025 Healthcare Conference. La société participera à une discussion informelle le 14 mai 2025 à 15h40 PT à Las Vegas, NV. Les investisseurs pourront suivre la présentation en direct via la section "News and Events" du site web de Kymera, avec une rediffusion disponible après l'événement.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung oraler Wirkstoffe zur Molekülzerstörung bei immunologischen Erkrankungen spezialisiert hat, hat seine Teilnahme an der BofA Securities 2025 Healthcare Conference angekündigt. Das Unternehmen wird am 14. Mai 2025 um 15:40 Uhr PT in Las Vegas, NV, an einem Gespräch teilnehmen. Investoren können die Präsentation live über den Bereich "News and Events" auf der Kymera-Website verfolgen; eine Wiederholung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT.
A live webcast of the presentation will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When is Kymera Therapeutics (KYMR) presenting at the BofA Securities Healthcare Conference 2025?
How can investors watch Kymera Therapeutics' (KYMR) presentation at the BofA Healthcare Conference?
What type of medicines is Kymera Therapeutics (KYMR) developing?
What is the current development stage of Kymera Therapeutics (KYMR)?
